Somaxon Pharmaceuticals

company

About

Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription

  • 251 - 500

Details

Last Funding Type
Series C
Last Funding Money Raised
$65M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2003
Number Of Employee
251 - 500
Operating Status
Active

Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketing proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.

Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$88M
Somaxon Pharmaceuticals has raised a total of $88M in funding over 2 rounds. Their latest funding was raised on Jun 6, 2005 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 6, 2005 Series C $65M 1 Detail
Jun 15, 2004 Series B $23M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Somaxon Pharmaceuticals is funded by 1 investors. BA Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
BA Venture Partners Series C